NeurAxis, Inc.
ASE: NRXSLive Quote
📈 ZcoreAI Score
Our AI model analyzes NeurAxis, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NRXS Z-Score →About NeurAxis, Inc.
Healthcare
Biotechnology
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
📊 Fundamental Analysis
NeurAxis, Inc. demonstrates a profit margin of -218.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 27.2% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -285.4%, which indicates that capital utilization is currently under pressure.
At a current price of $6.84, NRXS currently trades near the top of its 52-week range (83%) (Range: $1.33 - $7.97).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$76.52M
Trailing P/E
--
Forward P/E
-342.00
Beta (5Y)
1.89
52W High
$7.97
52W Low
$1.33
Avg Volume
147K
Day High
Day Low